Preliminary report of the use on adults of a recombinant yeast-derived hepatitis B vaccine manufactured by Instituto Butantan.

Abstract

Three 10 micrograms of the recombinant hepatitis B vaccine, manufactured by Instituto Butantan by original technology, were administered in an adult population, mean age 30 years old, following the 0, 1 and 6 months schedule immunization. The clinical trial was considered satisfactory in terms of immunogenicity (anti-HBs titers between 17.5-29500 IU/ l… (More)

Topics

Cite this paper

@article{Costa1997PreliminaryRO, title={Preliminary report of the use on adults of a recombinant yeast-derived hepatitis B vaccine manufactured by Instituto Butantan.}, author={A. A. Costa and Marta Inenami and E. Juarez and P D Llacen and Isa{\'i}as Raw}, journal={Revista do Instituto de Medicina Tropical de Sao Paulo}, year={1997}, volume={39 1}, pages={39-42} }